Health X Platform Limited (formerly known as sastasundar ventures Limited) has informed the stock exchanges of the completion of the transfer of the entire equity stake held by Mitsubishi Corporation in Sastasundar Healthbuddy Limited, a material subsidiary of the Company, to Envision India Fund. The transaction was completed on May 12, 2026, following the earlier disclosure made on February 25, 2026, regarding the execution of a Share Purchase Agreement by Sastasundar Healthbuddy Limited.

Transaction Details

The completed transaction involved the transfer of Mitsubishi Corporation's full shareholding in Sastasundar Healthbuddy Limited. The key details of the transaction are outlined below:

As a result of the transfer, Mitsubishi Corporation has ceased to be a shareholder of Sastasundar Healthbuddy Limited.

Board Acknowledgement and Regulatory Disclosure

The board of directors of Sastasundar Healthbuddy Limited took note of the said transfer at its board meeting held on May 15, 2026. Health X Platform Limited received the intimation from Sastasundar Healthbuddy Limited on May 15, 2026, at 10:46 AM. The disclosure has been made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The intimation was submitted by Pratap Singh, Company Secretary and Compliance Officer of Health X Platform Limited, in accordance with applicable regulatory requirements.

Health X Platform Limited, formerly known as sastasundar ventures , has submitted a revised Chartered Accountants' certificate to BSE Limited and National Stock Exchange of India Limited in support of its application for changing the company name from "Sastasundar Ventures Limited" to "Health X Platform Limited." The intimation was made under Regulation 30 of the SEBI (Listing of Obligations and Disclosure Requirements) Regulations, 2015, dated 24-04-2026.

Regulatory Compliance

The stock exchanges had requested the company to furnish a bifurcation of revenue in the CA certificate to affirm compliance with conditions prescribed in Regulation 45 of the SEBI (LODR) Regulations, 2015. The revised certificate, issued by J K V S & Co., Chartered Accountants, confirms that the company has not changed its name in the preceding one-year period, satisfying Regulation 45(1)(a).

Revenue Bifurcation Details

The auditors certified that more than fifty percent of the total revenue of the company, on a consolidated basis, is through the activity suggested by the new name. The detailed bifurcation of revenue for the period from 1st January, 2025 to 31st December, 2025 is as follows:

The figures for the period have been taken from the limited review financial results filed by the company with the stock exchanges. Healthcare activity revenue constitutes approximately 98.25% of the total consolidated revenue.

Shareholder Communication

The original certificate was attached to the Postal Ballot Notice dated January 7, 2026, which was sent to the stock exchanges and dispatched to shareholders on January 13, 2026. The company will send the revised CA certificate to shareholders at the next available opportunity, either through the Notice of General Meeting or such other mode as specified in the Companies Act, 2013 read with SEBI (Listing Obligation and Disclosure Requirement) Regulations 2015.

The statutory auditors' certificate was issued on April 9, 2026, by J K V S & Co., Firm Registration No. 318086E, with Utsav Saraf as the signing partner. The company's scrip codes are 533259 at BSE and SASTASUNDR at NSE.